Scientists hunt for genetic clues in rare lymphoma that turns deadly
NCT ID NCT06712459
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at a rare and aggressive form of lymphoma called transformed splenic marginal zone lymphoma (t-SMZL). The goal is to understand the genetic changes that happen when the disease transforms and becomes harder to treat. Researchers will analyze tumor samples from 100 adults to find patterns that could lead to better treatments in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward more specific and effective treatments for this aggressive lymphoma.
- What could go wrong
- This is an observational study, not a treatment trial. It aims to gather knowledge, not test a therapy, so direct patient benefit is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with transformed SMZL
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults aged 18 years or older, regardless of the gender; 2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease); 3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available; 4. Availability of the baseline and follow-up annotations. Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Transformed splenic marginal zone lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites in 7 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Columbia University
NOT_YET_RECRUITINGNew York, New York, 10032, United States
-
Fondazione IRCCS Policlinico San Matteo
RECRUITINGPavia, 27100, Italy
-
Hospital Clínic de Barcelona
RECRUITINGBarcelona, 08036, Spain
-
Hôpital Saint Louis
RECRUITINGParis, 75475, France
-
Oncology Institute of Southern Switzerland
NOT_YET_RECRUITINGBellinzona, 6500, Switzerland
-
University Hospitals Dorset
NOT_YET_RECRUITINGBournemouth, BH7 7DW, United Kingdom
-
Universitz Hospitals Leuven
NOT_YET_RECRUITINGLeuven, 3000, Belgium